Earlier this week, ResMed (NYSE:RMD) reported that it will release its quarterly earnings on Thursday afternoon, with Wall Street expecting around 10% year-on-year revenue growth and earnings of about ...
Resmed said its Chief Financial Officer will retire in May and announced plans to acquire a startup with an FDA de novo ...
By Bageshri Banerjee April 30 (Reuters) - Medical device maker ResMed beat third‑quarter profit estimates on Thursday, driven by strong demand for its medical devices, while appointing Aaron Bloomer ...
As competitor Philips continues to grapple with the effects of its long-standing recall of continuous positive airway pressure (CPAP) machines and other respiratory devices, ResMed is now issuing a ...
On April 15, 2026, JPMorgan initiated coverage of ResMed Inc. (NYSE:RMD) with an “Overweight” rating and an A$37.60 price ...
Q3 fiscal 2026 Management View “We delivered another set of strong results, including 11% growth in headline revenue or 8% growth on a constant currency basis… resulting in 21% growth in non-GAAP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results